COMPREHENSIVE® REVERSE SHOULDER Mini BasePlate
Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
1 other identifier
observational
100
1 country
5
Brief Summary
Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2013
Longer than P75 for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2013
CompletedFirst Submitted
Initial submission to the registry
March 5, 2014
CompletedFirst Posted
Study publicly available on registry
March 12, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2019
CompletedJuly 5, 2019
June 1, 2018
5.3 years
March 5, 2014
July 3, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Survivorship
The primary objective of this prospective clinical data collection is to evaluate survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
1 year
Secondary Outcomes (8)
Adverse Events (including dislocation)
3 year
Constant-Murley Shoulder Score
3 year
Radiographic Evaluation (Plain X-ray and CT)
3 year
Scapular Notching
3 year
Constant-Murley Shoulder Score
1 year
- +3 more secondary outcomes
Study Arms (1)
COMPREHENSIVE
Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
Interventions
Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
Eligibility Criteria
Therefore, patients / cases to be included in this study shall utilize the following inclusion criteria: 1. The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary. 2. Grossly deficient rotator cuff with severe arthropathy and/or * Previously failed shoulder joint replacement with a grossly deficient rotator cuff. * Primary total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency, or * Fracture total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency, or * Revision total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency.
You may qualify if:
- Comprehensive Reverse Shoulder Mini Base Plate and Mini Stem in a reverse shoulder configuration.
- The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary.
- Grossly deficient rotator cuff with severe arthropathy and/or
- Previously failed shoulder joint replacement with a grossly deficient rotator cuff.
- Primary total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency, or
- Fracture total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency, or
- Revision total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency.
You may not qualify if:
- Absolute contraindications include infection, sepsis, and osteomyelitis.
- Relative contraindications include:
- Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.
- Osteoporosis.
- Metabolic disorders which may impair bone formation.
- Osteomalacia.
- Distant foci of infections which may spread to the implant site.
- Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zimmer Biometlead
Study Sites (5)
Bunndang Seoul Nat'l Univ. Hospital
Seongnam-si, Seongnam, South Korea
Ewha Womans University Mokdong Hospital
Seoul, South Korea
Gangnam Sacred Heart Hospital
Seoul, South Korea
Kyung Hee Univ Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joo Han Oh, Ph.D.
Bundang Seoul Nat'l University Hospital
- PRINCIPAL INVESTIGATOR
Sang Jin Shin, Ph.D.
Ewha Womans University Mokdong Hospital
- PRINCIPAL INVESTIGATOR
Jae Chul Yoo, Ph. D.
Samsung Medical Center
- PRINCIPAL INVESTIGATOR
Yong Girl Rhee, Ph.D.
Kyung Hee Univ. Hospital
- PRINCIPAL INVESTIGATOR
Kyu Chul Noh, Ph.D.
Gangnam Sacred Heart Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 5, 2014
First Posted
March 12, 2014
Study Start
December 1, 2013
Primary Completion
April 1, 2019
Study Completion
June 1, 2019
Last Updated
July 5, 2019
Record last verified: 2018-06
Data Sharing
- IPD Sharing
- Will not share